ATE399777T1 - Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors - Google Patents

Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors

Info

Publication number
ATE399777T1
ATE399777T1 AT04749150T AT04749150T ATE399777T1 AT E399777 T1 ATE399777 T1 AT E399777T1 AT 04749150 T AT04749150 T AT 04749150T AT 04749150 T AT04749150 T AT 04749150T AT E399777 T1 ATE399777 T1 AT E399777T1
Authority
AT
Austria
Prior art keywords
pyrrole
modulators
liver
receptor
dione derivatives
Prior art date
Application number
AT04749150T
Other languages
German (de)
English (en)
Inventor
Jonas Bostroem
Kay Brickmann
Patrik Holm
Pernilla Sandberg
Marianne Swanson
Christer Westerlund
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE399777T1 publication Critical patent/ATE399777T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AT04749150T 2003-07-11 2004-07-08 Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors ATE399777T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316232.8A GB0316232D0 (en) 2003-07-11 2003-07-11 Therapeutic agents

Publications (1)

Publication Number Publication Date
ATE399777T1 true ATE399777T1 (de) 2008-07-15

Family

ID=27741983

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04749150T ATE399777T1 (de) 2003-07-11 2004-07-08 Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors

Country Status (25)

Country Link
US (1) US7432288B2 (enExample)
EP (1) EP1646626B1 (enExample)
JP (1) JP2007521312A (enExample)
KR (1) KR20060035748A (enExample)
CN (1) CN1823061A (enExample)
AR (1) AR045721A1 (enExample)
AT (1) ATE399777T1 (enExample)
AU (1) AU2004255999B2 (enExample)
BR (1) BRPI0412472A (enExample)
CA (1) CA2532056A1 (enExample)
DE (1) DE602004014773D1 (enExample)
ES (1) ES2308204T3 (enExample)
GB (1) GB0316232D0 (enExample)
IL (1) IL172760A0 (enExample)
IS (1) IS8293A (enExample)
MX (1) MXPA06000414A (enExample)
MY (1) MY135821A (enExample)
NO (1) NO20060081L (enExample)
RU (1) RU2006102130A (enExample)
SA (1) SA04250204B1 (enExample)
TW (1) TW200503691A (enExample)
UA (1) UA82109C2 (enExample)
UY (1) UY28408A1 (enExample)
WO (1) WO2005005417A1 (enExample)
ZA (1) ZA200600222B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE513823T1 (de) * 2004-08-17 2011-07-15 Simpson Biotech Co Ltd Mischung und verbindungen von mycelien von antrodia camphorata und deren verwendung
US7505238B2 (en) * 2005-01-07 2009-03-17 Agnes Neves Woo ESD configuration for low parasitic capacitance I/O
US7582629B2 (en) 2005-01-10 2009-09-01 Astrazeneca Ab Derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators
SE0500055D0 (sv) 2005-01-10 2005-01-10 Astrazeneca Ab Therapeutic agents 3
MX2008013477A (es) * 2006-04-28 2008-10-29 Esteve Labor Dr Compuestos biciclicos de tetrahidropirrol.
EP2069359B1 (en) 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
CN101456863B (zh) * 2007-12-14 2012-04-25 华北制药集团新药研究开发有限责任公司 Lxr激动剂及其制备方法和用途
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
CA2727252A1 (en) 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
AU2011336970A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Novel oxime derivatives as sphingosine 1-phosphate (S1P) receptor modulators
EP2646018B1 (en) 2010-12-03 2014-10-22 Allergan, Inc. Novel oxime azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators
US10669296B2 (en) 2014-01-10 2020-06-02 Rgenix, Inc. LXR agonists and uses thereof
CN109069461A (zh) 2016-01-11 2018-12-21 洛克菲勒大学 与髓源性抑制细胞相关的病症的治疗方法
EP3713575A4 (en) 2017-11-21 2021-08-25 Rgenix, Inc. POLYMORPHS AND THEIR USES
HUE067466T2 (hu) 2019-12-13 2024-10-28 Inspirna Inc Fémsók és alkalmazásuk
US11753374B2 (en) * 2020-11-18 2023-09-12 Southern Reserach Institute Compounds for the treatment of acute and chronic kidney disease

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4929999A (en) 1998-07-30 2000-02-21 Japan Tobacco Inc. Disubstituted maleimide compounds and medicinal utilization thereof
DE69922526T2 (de) * 1998-10-08 2005-06-02 Smithkline Beecham Plc, Brentford 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrol-2,5-dion als glykogen synthase kinase-3 inhibitor (gsk-3)
CA2377999A1 (en) * 1999-07-08 2001-01-18 Tularik Inc Compositions and methods for raising hdl cholesterol levels
WO2001013916A1 (en) 1999-08-20 2001-03-01 Sagami Chemical Research Center Drugs inhibiting cell death
GB0008264D0 (en) 2000-04-04 2000-05-24 Smithkline Beecham Plc Novel method and compounds

Also Published As

Publication number Publication date
UY28408A1 (es) 2005-02-28
US7432288B2 (en) 2008-10-07
UA82109C2 (uk) 2008-03-11
US20060235015A1 (en) 2006-10-19
SA04250204B1 (ar) 2008-03-23
IS8293A (is) 2006-02-09
IL172760A0 (en) 2006-04-10
WO2005005417A1 (en) 2005-01-20
ZA200600222B (en) 2007-04-25
CA2532056A1 (en) 2005-01-20
AR045721A1 (es) 2005-11-09
AU2004255999B2 (en) 2007-08-02
GB0316232D0 (en) 2003-08-13
MY135821A (en) 2008-07-31
KR20060035748A (ko) 2006-04-26
EP1646626B1 (en) 2008-07-02
JP2007521312A (ja) 2007-08-02
RU2006102130A (ru) 2007-08-20
BRPI0412472A (pt) 2006-09-19
AU2004255999A1 (en) 2005-01-20
MXPA06000414A (es) 2006-03-17
ES2308204T3 (es) 2008-12-01
HK1088320A1 (en) 2006-11-03
NO20060081L (no) 2006-02-08
EP1646626A1 (en) 2006-04-19
TW200503691A (en) 2005-02-01
CN1823061A (zh) 2006-08-23
DE602004014773D1 (de) 2008-08-14

Similar Documents

Publication Publication Date Title
ATE440085T1 (de) 3-substituierte 1,5-diphenylpyrazolderivate, die sich als cb1-modulatoren eignen
ATE399777T1 (de) Pyrrol-2,5-dionderivate als modulatoren des liver-x-rezeptors
ATE399776T1 (de) Pyrrol-2,5-dithionderivate als modulatoren des liver-x-rezeptors
ATE439357T1 (de) Indolylderivate als liver-x-rezeptormodulatoren
ATE451364T1 (de) Als modulatoren des dopamin-d3-rezeptors geeignete azabicycloä3.1.0ühexanderivate
ATE420881T1 (de) Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors
EP1773768B8 (en) Pyrrole derivatives as pharmaceutical agents
MA28391B1 (fr) Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines
DE60317630D1 (de) Indol, azaindol und verwandte heterocyclische pyrrolidin-derivate
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
EP1717225A4 (en) BICYCLIC AMIDE DERIVATIVES
EP1689389A4 (en) INDOLE COMPOUNDS
ATE387202T1 (de) Pyrrolidinderivate als histaminrezeptor-liganden
DE602006013878D1 (de) Heterocyclische verbindungen, ihre herstellung und ihre verwendung als antibakterielle mittel
ZA200804349B (en) 1,1-dioxo-thiomorpholinyl indolyl methanone derivatives for use as H3 modulators
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
AU2003205964A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003214520A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
BRPI0509256A (pt) derivados de pirrolidina-3,4-dicarboxamida
EP1811842A4 (en) IMMUNE ACTIVATION COMPOSITIONS BASED ON 3,3'-DIINDOLYLMETHANE
AU2003223010A1 (en) Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
AU2003278403A1 (en) 1-alkylpiperazinyl-pyrrolidin-2, 5-dione derivatives as adrenergic receptor antagonist
DE602004009583D1 (de) Piperidin- oder 8-azabicycloä3.2.1üoct-3-ylderivate, die sich als modulatoren der chemokinrezeptoraktivität eignen
AP2005003425A0 (en) Heterobicyclic compounds used as fungicides.
DE602004006424D1 (de) Piperidinderivate als ccr5-rezeptormodulatoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties